Ethicon Buying VC-Backed Acclarent for $785 Million
Ethicon, a subsidiary of a Johnson & Johnson (NYSE: JNJ), has agreed to acquire Acclarent Inc., a Menlo Park, Calif.-based developer of surgical devices for treating ear, nose and throat ailments. The deal is valued at $785 million in cash. Acclarent has raised just over $100 million in VC funding, from firms like Johnson & New Enterprise Associates, Delphi Ventures, Versant Ventures, Meritech Capital Partners and Johnson Development Corp. Acclarent canceled a proposed $86.25 million IPO in December 2008, citing "unfavorable market conditions."
16 December 2009•3 mins read
